Sorry, you need to enable JavaScript to visit this website.

Fecal Proteomics Suggest Potential Biomarkers for Non-Alcoholic Fatty Liver Disease and Steatohepatitis

TitoloFecal Proteomics Suggest Potential Biomarkers for Non-Alcoholic Fatty Liver Disease and Steatohepatitis
Tipo di pubblicazioneArticolo su Rivista peer-reviewed
Anno di Pubblicazione2026
AutoriNegroni, Anna, Pieroni Luisa, Fiaschini N., Palone Francesca, Mancuso Mariateresa, and Vitali Roberta
RivistaProteomics Clin Appl
Volume20
Issue4
Paginazionee70047
Data di pubblicazione2026 Jul
ISSN18628354
Parole chiaveAnimals, Biomarkers, feces, male, Mice, Mice, Inbred C57BL, Non-alcoholic Fatty Liver Disease, Proteomics
Abstract

BACKGROUND AND AIMS: Non-alcoholic Fatty Liver Disease (NAFLD) affects about a quarter of the world's population. Liver biopsy remains the gold standard for diagnosing the progressive form of NAFLD called Non-alcoholic Steatohepatitis (NASH) but it is invasive, prone to sampling errors and observer variability, and impractical for widespread use. Fecal non-invasive biomarkers have emerged as a new approach to diagnose, stage, and monitor NAFLD over time.

METHODS: Proteomic analysis was performed using Liquid Chromatography-Mass Spectrometry (LC-MS/MS) in fecal samples derived from mice fed with high fat and sugar diet representing NAFLD model and with the addition of 5 cycles of dextran-sulphate in drinking water to induce a NASH.

RESULTS: Qualitative and quantitative different protein profiles resulted in a comparison between the three groups of mice. An enrichment analysis of differentially expressed proteins explores the molecular pathways involved. A selection of the most significant modulated proteins between groups was performed. The proteins Transthyretin, Kallikrein1 and Trefoil Factor 3 were validated by ELISA.

CONCLUSION: Our exploratory discovery study identified several proteins that, alone or in combination, enable a good separation between NASH, NAFLD and healthy mice, highlighting their potential as key targets for future research.

DOI10.1002/prca.70047
Alternate JournalProteomics Clin Appl
Citation Key14288
PubMed ID42216306
Grant List / / Project ECS 0000024 Rome Technopole, - CUP B83C22002820006 /
/ / National Recovery and Resilience Plan (NRRP), Mission 4, Component 2 Investment 1.5, funded from the European Union - NextGenerationEU /